DAX
18.163,52 -90,66 (-0,50%) Euro Stoxx 50
4.907,30 -40,43 (-0,82%) Dow Jones 30
39.150,33 +15,57 (+0,04%) Gold
2.334,70 -34,30 (-1,45%) EUR/USD
1,0697 -0,0009 (-0,09%) Bitcoin EUR
60.211,77 +115,61 (+0,19%)
Zealand Pharma A/S (22ZA.F)
Zealand Pharma A/S
Sydmarken 11
Søborg 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com
Sektor(en):
Branche:
Vollzeitmitarbeiter: 270
Beschreibung
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Corporate Governance
Zealand Pharma A/Ss ISS Governance QualityScore, Stand 1. Juni 2024, lautet 3. Die grundlegenden Scores sind Audit: 5, Vorstand: 1, Shareholderrechte: 1, Kompensation: 8.
